Onglyza Den Europæiske Union - islandsk - EMA (European Medicines Agency)

onglyza

astrazeneca ab - saxagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Torisel Den Europæiske Union - islandsk - EMA (European Medicines Agency)

torisel

pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - Æxlishemjandi lyf - nýrna-klefi carcinomatorisel er ætlað fyrir fyrsta lína meðferð fullorðinn sjúklinga með langt nýrna-klefi krabbamein (rcc) sem hafa minnsta kosti þrisvar sex bata hættu þáttum. skikkju-klefi lymphomatorisel er ætlað fyrir meðferð fullorðinn sjúklinga með fallið og / eða óviðráðanleg skikkju-eitlaæxli (sáust oftar).

Vistide Den Europæiske Union - islandsk - EMA (European Medicines Agency)

vistide

gilead sciences international limited - cidófóvír - cytomegalovirus retinitis - veirueyðandi lyf til almennrar notkunar - vistide er ætlað til meðferðar við cýtómegalóveiru retinitis hjá sjúklingum með fengið ónæmisbrestsheilkenni (aids) og án skerta nýrnastarfsemi. vistide ætti aðeins að nota þegar aðrir lyf eru talin óviðeigandi.

Lumoxiti Den Europæiske Union - islandsk - EMA (European Medicines Agency)

lumoxiti

astrazeneca ab - moxetumomab pasudotox - hvítblæði, hairy cell - Æxlishemjandi lyf - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Quviviq Den Europæiske Union - islandsk - EMA (European Medicines Agency)

quviviq

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - svefntruflun og viðhald - psycholeptics - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Duloxetin Krka Magasýruþolið hart hylki 30 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

duloxetin krka magasýruþolið hart hylki 30 mg

krka, d.d., novo mesto - duloxetinum hýdróklóríð - magasýruþolið hart hylki - 30 mg

Aritavi Magasýruþolið hart hylki 30 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

aritavi magasýruþolið hart hylki 30 mg

teva b.v.* - duloxetinum hýdróklóríð - magasýruþolið hart hylki - 30 mg

Aritavi Magasýruþolið hart hylki 60 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

aritavi magasýruþolið hart hylki 60 mg

teva b.v.* - duloxetinum hýdróklóríð - magasýruþolið hart hylki - 60 mg

Duloxetin Krka Magasýruþolið hart hylki 60 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

duloxetin krka magasýruþolið hart hylki 60 mg

krka, d.d., novo mesto - duloxetinum hýdróklóríð - magasýruþolið hart hylki - 60 mg